CSF proteomic profiling with amyloid/tau positivity identifies distinctive sex-different alteration of multiple proteins involved in Alzheimer’s disease

Anh N. Do,Muhammad Ali,Jigyasha Timsina,Lihua Wang,Daniel Western,Menghan Liu,Jessie Sanford,Matitee Rosende-Roca,Merce Boada,Raquel Puerta,Ted Wilson,Agustin Ruiz,Pau Pastor,the Alzheimer’s Disease Neuroimaging Initiative (ADNI),Tony Wyss-Coray,Carlos Cruchaga,Yun Ju Sung

DOI: https://doi.org/10.1101/2024.03.15.24304164

2024-03-16

Abstract:In Alzheimer’s disease (AD), the most common cause of dementia, females have higher prevalence and faster progression, but sex-specific molecular findings in AD are limited. Here, we comprehensively examined and validated 7,006 aptamers targeting 6,162 proteins in cerebral spinal fluid (CSF) from 2,077 amyloid/tau positive cases and controls to identify sex-specific proteomic signatures of AD. In discovery (N=1,766), we identified 330 male-specific and 121 female-specific proteomic alternations in CSF (FDR <0.05). These sex-specific proteins strongly predicted amyloid/tau positivity (AUC=0.98 in males; 0.99 in females), significantly higher than those with age, sex, and APOE-ε4 (AUC=0.85). The identified sex-specific proteins were well validated (r≥0.5) in the Stanford study (N=108) and Emory study (N=148). Biological follow-up of these proteins led to sex differences in cell-type specificity, pathways, interaction networks, and drug targets. Male-specific proteins, enriched in astrocytes and oligodendrocytes, were involved in postsynaptic and axon-genesis. The male network exhibited direct connections among 152 proteins and highlighted PTEN, NOTCH1, FYN, and MAPK8 as hubs. Drug target suggested melatonin (used for sleep-wake cycle regulation), nabumetone (used for pain), daunorubicin, and verteporfin for treating AD males. In contrast, female-specific proteins, enriched in neurons, were involved in phosphoserine residue binding including cytokine activities. The female network exhibits strong connections among 51 proteins and highlighted JUN and 14-3-3 proteins (YWHAG and YWHAZ) as hubs. Drug target suggested biperiden (for muscle control of Parkinson’s disease), nimodipine (for cerebral vasospasm), quinostatin and ethaverine for treating AD females. Together, our findings provide mechanistic understanding of sex differences for AD risk and insights into clinically translatable interventions.

Neurology

What problem does this paper attempt to address?

This paper aims to explore the proteomic characteristics of gender differences in Alzheimer's disease (AD), especially to identify protein changes specific to men and women through the amyloid - tau positive status in cerebrospinal fluid (CSF). Specifically, the researchers hope to reveal the different roles of gender in the pathogenesis of AD through large - scale proteomic analysis, and explore the potential impact of these gender - specific protein changes on the diagnosis and treatment of AD.

### Problems the paper attempts to solve:

1. **Molecular mechanisms of gender differences in AD**: Although it is known that women are more likely to develop AD and the disease progresses more rapidly than men, research on gender - specific molecular mechanisms is relatively limited. The paper attempts to fill this knowledge gap through large - scale proteomic analysis.

2. **Early diagnosis and intervention**: Since changes in amyloid - tau levels in CSF can be detected ten years before the appearance of clinical symptoms, the paper attempts to use these biomarkers to achieve early diagnosis and potential intervention of AD.

3. **Gender - specific drug targets**: By identifying protein changes specific to men and women, the paper also hopes to find potential drug targets for different genders, thus providing new ideas for personalized treatment.

### Main findings:

- **Gender - specific protein changes**: The researchers found 330 male - specific and 121 female - specific protein changes among 1,766 participants, and these proteins can highly predict the amyloid - tau positive status.
- **Biological pathways**: Male - specific proteins are mainly involved in synaptic structure and axonal activity, while female - specific proteins are related to receptor binding, inflammatory response, and DNA - binding transcriptional activation activity.
- **Cell - type specificity**: Male - specific proteins are enriched in astrocytes and oligodendrocytes, while female - specific proteins are enriched in neurons.
- **Drug targets**: The study proposed potential drug targets for men and women, such as melatonin, nabumetone, daunorubicin, and verteporfin in men, and biperiden, nimodipine, quinostatin, and ethaverine in women.

Through these findings, the paper provides new insights into the mechanisms of gender differences in AD and lays the foundation for the development of gender - specific diagnosis and treatment methods.